Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
NOVARTIS

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
NOVARTIS

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
NOVARTIS

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
NOVARTIS

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
NOVARTIS

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
NOVARTIS

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
NOVARTIS

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
NOVARTIS

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
NOVARTIS

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
NOVARTIS

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
NOVARTIS

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
NOVARTIS

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
NOVARTIS

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
NOVARTIS

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
NOVARTIS

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
NOVARTIS

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
NOVARTIS

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
NOVARTIS

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
NOVARTIS

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
NOVARTIS

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
NOVARTIS

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
NOVARTIS

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
NOVARTIS

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
NOVARTIS

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
NOVARTIS

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
NOVARTIS

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
NOVARTIS

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
NOVARTIS

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
NOVARTIS

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
NOVARTIS

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
NOVARTIS

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
NOVARTIS

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
NOVARTIS

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
NOVARTIS

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
NOVARTIS

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
NOVARTIS

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
NOVARTIS

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
NOVARTIS

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
NOVARTIS

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
NOVARTIS

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
NOVARTIS

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
NOVARTIS

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
NOVARTIS

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
NOVARTIS

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
NOVARTIS

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
NOVARTIS

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
NOVARTIS

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
NOVARTIS

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
NOVARTIS

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
NOVARTIS

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
NOVARTIS

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
NOVARTIS

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
NOVARTIS

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
NOVARTIS

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
NOVARTIS

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
NOVARTIS

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
NOVARTIS

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
NOVARTIS

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
NOVARTIS

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
NOVARTIS

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
NOVARTIS

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
NOVARTIS

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
NOVARTIS

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
NOVARTIS

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
NOVARTIS

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
NOVARTIS

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
NOVARTIS

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
NOVARTIS

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
NOVARTIS

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
NOVARTIS

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
NOVARTIS

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
NOVARTIS

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
Acerta

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
NOVARTIS

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy

Type of Cancer
Ovarian Cancer

Sponsor
AstraZeneca

Protocol Number
D108161003

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910